DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan (T-DXd)|DRUG: Ado-trastuzumab emtansine (T-DM1)
Sponsor: Daiichi Sankyo
Collaborators: Daiichi Sankyo Co., Ltd.|AstraZeneca